Prescription of Direct Oral Anticoagulant Affects Activated Clotting Time During Percutaneous Coronary Intervention and Bleeding Events

Prescription of Direct Oral Anticoagulant Affects Activated Clotting Time During Percutaneous Coronary Intervention and Bleeding Events - Prescription of Direct Oral Anticoagulant Affects Activated Clotting Time During Percutaneous Coronary Intervention and Bleeding Events

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047650

Enrollment

250

Registered

2022-05-30

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent PCI in the cardiovascular centers in Japan between February 2017 and April 2018.

Exclusion criteria

Exclusion criteria: Patients receiving warfarin at the time of percutaneous coronary intervention (PCI) and patients whose activated clotting time was not measured at the time of PCI initiation were excluded.

Design outcomes

Primary

Measure	Time frame
Prognosis from the end of percutaneous coronary revascularization to 30 days (bleeding events, embolic events)	—

Secondary

Measure	Time frame
Kinetic changes in activated coagulation time during percutaneous coronary revascularization (at the start and 30 minutes after the procedure)	—

Countries

Japan

Contacts

Public ContactEiji Shibahashi

Tokyo Womens Medical University Department of Cardiology

shiabahashi.e@gmail.com81-3-3353-8111

Outcome results